Biotechnology company Amgen (NASDAQ:AMGN) revealed on Tuesday the completion of the acquisition of the acquisition of 49% of shares of Amgen Astellas BioPharma KK (AABP) from Astellas.
Amgen Astellas BioPharma KK (AABP) is reportedly a joint venture between Amgen and Astellas established in 2013.
Upon closing, AABP is Amgen's wholly-owned affiliate in Japan and has been renamed Amgen KK.
Amgen KK focuses on the development of innovative medicines, and addressing severe unmet medical needs of patients in Japan by bringing Amgen's global pipelines, ranging from cardiovascular diseases, cancer, bone diseases through neurological diseases.
Since 2011, Amgen has expanded its geographic presence from 50 to 100 countries, enabling the company to play a growing role in serving the rapidly increasing demand for better healthcare around the world. In 2019, it invested more than USD4bn in research and development to advance numerous potential new medicines across all stages of our pipeline. In Japan, it advances treatments for serious illnesses.
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial